[1]陈志军,曹克鑫,甘绍印,等.胸腺肽α1联合顺铂和氟尿嘧啶新辅助化疗治疗食管癌疗效观察[J].新乡医学院学报,2021,38(3):268-272.[doi:10.7683/xxyxyxb.2021.03.013]
　CHEN Zhijun,CAO Kexin,GAN Shaoyin,et al.Therapeutic effect of thymosin α1 combined with cisplatin and fluorouracil neoadjuvant chemotherapy on esophageal cancer[J].Journal of Xinxiang Medical University,2021,38(3):268-272.[doi:10.7683/xxyxyxb.2021.03.013]
点击复制

胸腺肽α1联合顺铂和氟尿嘧啶新辅助化疗治疗食管癌疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年3
页码:
268-272
栏目:
临床研究
出版日期:
2021-03-05

文章信息/Info

Title:
Therapeutic effect of thymosin α1 combined with cisplatin and fluorouracil neoadjuvant chemotherapy on esophageal cancer
作者:
陈志军; 曹克鑫; 甘绍印; 闫二帅; 王忠民
（新乡医学院第一附属医院胸外科一病区，河南　卫辉　453100）
Author(s):
CHEN Zhijun; CAO Kexin; GAN Shaoyin; YAN Ershuai; WANG Zhongmin
(Department of Thoracic Surgery,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China)
关键词:
胸腺肽α1; 新辅助化疗; 食管癌; 微RNA-451; 微RNA-21
Keywords:
thymosin α1neoadjuvant chemotherapyesophageal cancermicroRNA-451microRNA-21
分类号:
R735.1
DOI:
10.7683/xxyxyxb.2021.03.013
文献标志码:
A
摘要:
目的　探讨胸腺肽α1联合顺铂和氟尿嘧啶新辅助化疗对食管癌患者的临床效果。方法　选择2017年9月至2019年12月新乡医学院第一附属医院收治的124例食管癌患者为研究对象，根据治疗方案将患者分为对照组和观察组，每组62例。所有患者术前给予顺铂和氟尿嘧啶进行新辅助化疗2个周期。观察组患者于新辅助化疗开始前3 d至新辅助化疗结束皮下注射胸腺肽α1。比较2组患者治疗前后细胞免疫功能、血清炎症因子水平、微RNA（miR）-451和miR-21相对表达量及外科手术治疗效果、3级和4级不良反应发生率。结果　治疗前2组患者外周血中CD3+、CD4+、CD8+水平及CD4+/CD8+、CD16+/CD56+比值比较差异无统计学意义 （P> 0.05) 。治疗24、45 d及术后7 d，2组患者外周血中CD3+、CD4+、CD8+水平及CD16+/CD56+比值显著低于治疗前（P<0.05)，cd4>+/CD8+比值显著高于治疗前(P<0.05)。治疗24、45 d及术后7 d，观察组患者外周血中CD3+、CD4+、CD8+水平及CD4+/CD8+、CD16+/CD56+比值显著高于对照组(P<0.05)。治疗前2组患者血清中白细胞介素（IL）-6、IL-8、肿瘤坏死因子-α（TNF-α）、miR-451和miR-21水平比较差异无统计学意义（P>0.05）。2组患者治疗后血清中IL-6、IL-8、TNF-α、miR-451和miR-21水平均显著低于治疗前（P<0.05）。治疗后观察组患者血清中il-6、il-8、tnf-α、mir-451和mir-21水平均显著低于对照组（>P<0.05）。观察组患者手术切除率和完全性切除率均显著高于对照组（>P<0.05）。2组患者均未发生3、4级肺炎、周围神经损害、肝功能损害及肾功能损害。观察组患者3、4级呕吐、粒细胞减少、血红蛋白减少、血小板减少、食管炎不良反应发生率均显著低于对照组（>P<0.05）。>结论　胸腺肽α1联合顺铂和氟尿嘧啶新辅助化疗对食管癌患者的临床疗效较好。undefinedundefinedundefinedundefinedundefined
Abstract:
Objective　To investigate the clinical effect of thymosin α1 combined with cisplatin and fluorouracil neoadjuvant chemotherapy on patients with esophageal cancer.Methods　　A total of 124 patients with esophageal cancer admitted to the First Affiliated Hospital of Xinxiang Medical University from September 2017 to December 2019 were selected as the research objects.The patients were divided into control group and observation group according to different treatment plans,with 62 cases in each group.All patents were given cisplatin and fluorouracil neoadjuvant chemotherapy for 2 cycles before surgery.The patients in the observation group were injected subcutaneously with thymosin α1 from 3 days before the start of neoadjuvant chemotherapy to the end of neoadjuvant chemotherapy.The cellular immune function,serum inflammatory factor levels,relative expression levels of microRNA(miR)-451 and miR-21 before and after treatment and surgical treatment effect,incidence of grade 3 and 4 adverse reactions of the patients between the two groups were compared.Results　Before treatment,there was no significant difference in the levels of CD3+,CD4+,CD8+and the ratio of CD4+/CD8+and CD16+/CD56+in the peripheral blood of the patients between the two groups (P>0.05).The levels of CD3+,CD4+,CD8+and the ratio of CD16+/CD56+in the peripheral blood of the patients at 24 d,45 d of treatment and 7 d after operation were significantly lower than those before treatment in the two groups (P<0.05),and the CD4+/CD8+ ratio was significant higher than that before treatment (P<0.05).At 24,45 d of treatment and 7 d after operation,the levels of CD3+,CD4+,CD8+and the ratio of CD4+/CD8+and CD16+/CD56+in the peripheral blood of the patients in the observation group were significantly higher than those in the control group (P<0.05).Before treatment,there was no significant difference in the levels of serum interleukin（IL）-6,IL-8,tumor necrosis factor-α （TNF-α）,miR-451 and miR-21 of patients between the two groups (P>0.05).The levels of serum IL-6,IL-8,TNF-α,miR-451 and miR-21 of the patients after treatment were significantly lower than those before treatment in the two groups (P<0.05).After treatment,the levels of serum IL-6,IL-8,TNF-α,miR-451 and miR-21 of the patients in the observation group were significantly lower than those in the control group (P<0.05).The rates of surgical resection and complete resection of the patients in the observation group were significantly higher than those in the control group (P<0.05).No patients in the two groups developed grade 3 and 4 pneumonia,Peripheral nerve damage,liver damage or kidney damage.The incidence of adverse reactions of grade 3 and 4 vomiting,neutropenia,hemoglobin reduction,thrombocytopenia,and esophagitis of the patients in the observation group were significantly lower than those in the control group (P<0.05).Conclusion　Thymosin α1 combined with cisplatin and fluorouracil neoadjuvant chemotherapy has a good clinical effect on patients with esophageal cancer.

参考文献/References:

［1］　NAVEED M,KUBILIUN N.Endoscopic treatment of early-stage esophageal cancer［J］.Curr Oncol Rep,2018,20(9):71.
［2］　WATANABE M,MINE S,NISHIDA K,et al.Reconstruction after esophagectomy for esophageal cancer patients with a history of gastrectomy［J］.Gen Thorac Cardiovas,2016,64(8):1-7.
［3］　罗孟亚男，苏文利，李有强，等.新辅助同步放化疗对食管癌腔镜术患者肿瘤组织细胞活性的影响［J］.现代消化及介入诊疗,2019,24(3):231-235.
［4］　WANG F,LI B,FU P,et al.Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer［J］.Int J Pharm,2018,547(1-2):611-620.
［5］　MAMOORI A,WAHAB R,VIDER J,et al.The tumour suppressor effects and regulation of cancer stem cells by macrophage migration inhibitory factor targeted miR-451 in colon cancer［J］.Gene,2019,697:165-174.
［6］　YAO L H,WANG G R,CAI Y,et al.The expressions and diagnostic values of miR-18a and miR-21 in esophageal cancer［J］.Chin J Oncol,2019,41(2):107-111.
［7］　郭二亮，张金峰，杨英男，等.食管癌肿瘤标志物的研究进展［J］.现代肿瘤医学，2018，26(11):1783-1786 .
［8］　高云飞，罗洞波，刘翼，等.胸腹腔镜对食管癌根治术患者炎症因子、肺功能及预后的影响［J］.肿瘤学杂志,2018,24(1):42-46.
［9］　王军，肖林林，程云杰.局部进展期食管癌新辅助治疗研究进展［J］.中华放射肿瘤学杂志,2018,27(8):709-720.
［10］　程良，付茂勇，杨毫，等.食管鳞癌新辅助化疗的研究进展［J］.中华消化外科杂志，2019，18(6):604-606.
［11］　PARK R,WILLIAMSON S,KASI A,et al.Immune therapeutics in the treatment of advanced gastric and esophageal cancer［J］.Anticancer Res,2018,38(10):5569-5580.
［12］　赵美淇，梁新强，刘海洲，等.肿瘤患者外周血T淋巴细胞亚群及NK细胞比例检测的临床意义［J］.中国实验诊断学,2019,23(3):381-384.
［13］　简洁君,李国义,余滋中，等.紫杉类-顺铂-氟尿嘧啶联合诱导化疗对晚期头颈癌疗效和安全性的Meta分析［J］.临床耳鼻咽喉头颈外科杂志,2016,30（4）:282-287.
［14］　毛雨秋,庞雯雯.胸腺肽联合化疗治疗老年胃癌患者的临床疗效及对免疫功能、血清MMP-2、MMP-9水平的影响［J］.肿瘤学杂志,2018,24(6):587-591.
［15］　张伟，于在诚.食管癌患者不同术式围手术期细胞免疫与体液免疫的监测分析［J］.广东医学,2015,36(10):1545-1547.
［16］　朱富祖，白毅平，莫利群.丰富环境对食管癌患者围术期心--理状况及认知功能影响［J］.中国现代医学杂志,2018,28(15):102-106.
［17］　郑艳,黄晋,王卫广.胸腺肽α1联合血必净注射液对重症肺炎合并脓毒症患者血清CRP、TNF-α、IL-6、IL-8水平的影响［J］.中国生化药物杂志,2017,37(3):165-167.
［18］　LI L,GAO R,YU Y,et al.Tumor suppressor activity of miR-451:identification of CARF as a new target［J］.Sci Rep,2018,8(1):375.
［19］　ZHANG Z,WANG J,WANG X,et al.MicroRNA-21 promotes proliferation,migration,and invasion of cervical cancer through targeting TIMP3［J］.Arch Gyneco Obstet,2018,297(2):433-442.
［20］　晏明珠.胸腺肽α1注射液联合FOLFIRI化疗方案治疗晚期胃癌的疗效及其对血清T淋巴细胞亚群水平的影响［J］.肿瘤基础与临床,2019,32(6):518-520.

相似文献/References:

[1]于　鹤,刘光新.新辅助化学治疗联合肿瘤细胞减灭术治疗晚期卵巢癌疗效观察[J].新乡医学院学报,2020,37(3):258.[doi:10.7683/xxyxyxb.2020.03.014]
　YU He,LIU Guangxin.Effect of neoadjuvant chemotherapy combined with cytoreductive surgery in the treatment of advanced ovarian cancer[J].Journal of Xinxiang Medical University,2020,37(3):258.[doi:10.7683/xxyxyxb.2020.03.014]

更新日期/Last Update: 2021-03-05